Emergent BioSolutions has acquired Adapt Pharma in a deal valued at up to $735m.
Adapt Pharma will receive an upfront payment of $635m apart from $100m in the form of milestone payments through 2022. Emergent paid $575m in cash and $60m in common stock at the closing of the transaction.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The transaction was funded through cash-in-hand and funds from a $1.05bn syndicated senior secured loan.
Emergent BioSolutions is a global life sciences company, while Adapt Pharma is a privately-held company. Both are based in the US.
The acquisition will add Adapt Pharma’s proprietary NARCAN® (naloxone HCI) Nasal Spray, a popular emergency drug used for opioid overdose, to its product portfolio.
Pediapharm has completed the acquisition of Medexus and Medac Pharma for a total $67.62m.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe acquisition of Medexus included a consideration of approximately C$23m ($17.62m) and issue of 67.6 million common shares priced at C$0.34 ($0.24) of Pediapharm to stockholders of Medexus.
Pediapharm acquired Medac Pharma for a consideration of $50m, including $13.1m in cash along with the issue of 7.26 million units priced at $0.261 a unit.
Pediapharm has also entered a manufacturing and supply agreement with medac GmbH and Medac Pharma. medac GmbH will supply products to Pediapharm. The transaction is effective for 12 years from the date of the acquisition.
The existing supply agreement between Medexus and medac GmbH was also extended for 12 years.
Pediapharm is a pharmaceutical company, while Medexus is a pharmaceutical organisation that provides prescription and over-the-counter drugs. Both are based in Canada. Medac Pharma is a US-based pharmaceutical company focused on rheumatology.
Adynxx has signed a merger agreement with Alliqua BioMedical to acquire the outstanding stock of the latter on a completely-diluted basis.
The merger will create a clinical-stage company focussed on the development of non-opioid therapies for the treatment of pain.
Adynxx shareholders will hold 86% interest in the unified entity, while the remaining will be held by the shareholders of Alliqua.
The merger is expected to close in the first quarter of 2019, subject to approval from the stockholders of the companies.
Adynxxis a clinical-stage biotechnology company targeting pain through transformative technology platform, while Alliqua is involved in the development and manufacturing of electron-beam cross-linked hydrogels. Both parties are US-based.
